Merad/B. Braun Promote Cardiovasular Disease Treatment

MEDRAD, Inc., Warrendale, Pa., has entered into a co-marketing and trademark license agreement with B. Braun Melsungen AG (Melsungen, Germany) to promote the PaccocathA[R] technology, a unique and clinically tested technology used to treat blocked vessels without stenting. The Paccocath technology has been shown in multiple clinical trials to keep the artery open wider (reduce late lumen loss) over time in patients with Peripheral Arterial Disease and Coronary Artery Disease (CAD). The Paccocath technology will be used in both MEDRAD's and B. Braun's drug-eluting balloons. Under the agreement, B. Braun is permitted to use the Paccocath trademark in connection with promotion and marketing of its drug eluting balloon products. Both companies will also feature the Paccocath technology at various tradeshows, sponsored educational seminars and symposia, and on respective informational websites.